Overview

Overview

There is a Change Occurring in Pulmonary Medicine:

Indi’s overall mission is to fill a gap in health care delivery and provide physicians with information that will enable them to make a more informed health care decision and plan a care strategy for their patient.

Xpresys Lung is the first test to provide pulmonologists with molecular evidence to better assist in identifying lung nodules (8-30 mm in size) with a likely benign probability up to 98%. By integrating Xpresys Lung into a patient’s care strategy, physicians may be able to prevent unnecessary invasive procedures, and as a result, improve patient outcomes, reduce complications, and reduce costs to the healthcare system.

 
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue